Article
Gefitinib enhances cytotoxicities of antimicrotubule agents in non-small-cell lung cancer cells exhibiting no sensitizing epidermal growth factor receptor mutation.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer - 1 Aug 2012
Tsai Chun-Ming, Chiu Chao-Hua, Chang Kao-Ting, Chen Jen-Ting, Lai Chun-Liang, Chen Yuh-Min, Hsiao Shih-Yin
Abstract excerpt
INTRODUCTIONS: Although randomized clinical trials showed no benefit from combining epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) with standard chemotherapy for advanced non-small-cell lung cancer (NSCLC), better results might be obtained by combining EGFR-TKI with individual agents that are substrates for the adenosine triphosphate binding cassette transporters (ABCTs) because...
Topics
- Antineoplastic Agents
- Antineoplastic Combined Chemotherapy Protocols
- Apoptosis
- Blotting, Western
- Carcinoma, Non-Small-Cell Lung
- Cell Line, Tumor
- Drug Resistance, Multiple
- Drug Resistance, Neoplasm
- Drug Synergism
- ErbB Receptors
- Gefitinib